A citation-based method for searching scientific literature

Julia Roeper, Sylke Kurz, Christian Grohé, Frank Griesinger. Future Oncol 2021
Times Cited: 3







List of co-cited articles
3 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity



Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer.
Tony S Mok, Yi-Long Wu, Myung-Ju Ahn, Marina C Garassino, Hye R Kim, Suresh S Ramalingam, Frances A Shepherd, Yong He, Hiroaki Akamatsu, Willemijn S M E Theelen,[...]. N Engl J Med 2017
66

Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.
Jean-Charles Soria, Yuichiro Ohe, Johan Vansteenkiste, Thanyanan Reungwetwattana, Busyamas Chewaskulyong, Ki Hyeong Lee, Arunee Dechaphunkul, Fumio Imamura, Naoyuki Nogami, Takayasu Kurata,[...]. N Engl J Med 2018
66

Brain metastases in oncogene-driven non-small cell lung cancer.
Makoto Nishino, Kenzo Soejima, Tetsuya Mitsudomi. Transl Lung Cancer Res 2019
13
33


Crosstalk between RNA m6A Modification and Non-coding RNA Contributes to Cancer Growth and Progression.
Fengsheng Dai, Yongyan Wu, Yan Lu, Changming An, Xiwang Zheng, Li Dai, Yujia Guo, Linshi Zhang, Huizheng Li, Wei Xu,[...]. Mol Ther Nucleic Acids 2020
23
33

N6-methyladenosine RNA modification in cancer therapeutic resistance: Current status and perspectives.
Zhijie Xu, Bi Peng, Yuan Cai, Geting Wu, Jinzhou Huang, Ming Gao, Guijie Guo, Shuangshuang Zeng, Zhicheng Gong, Yuanliang Yan. Biochem Pharmacol 2020
13
33

m6A modification in RNA: biogenesis, functions and roles in gliomas.
Yuhao Zhang, Xiuchao Geng, Qiang Li, Jianglong Xu, Yanli Tan, Menglin Xiao, Jia Song, Fulin Liu, Chuan Fang, Hong Wang. J Exp Clin Cancer Res 2020
12
33

METTL3 potentiates resistance to cisplatin through m6 A modification of TFAP2C in seminoma.
Jingchao Wei, Yinghao Yin, Jun Zhou, Hanfei Chen, Jingxuan Peng, Jianfu Yang, Yuxin Tang. J Cell Mol Med 2020
14
33

METTL3 Induces AAA Development and Progression by Modulating N6-Methyladenosine-Dependent Primary miR34a Processing.
Lintao Zhong, Xiang He, Haoyu Song, Yili Sun, Guojun Chen, Xiaoyun Si, Jie Sun, Xiaoqiang Chen, Wangjun Liao, Yulin Liao,[...]. Mol Ther Nucleic Acids 2020
10
33

KIAA1429 promotes osteosarcoma progression by promoting stem cell properties and is regulated by miR-143-3p.
Qicai Han, Jie Yang, Hao Yang, Chao Li, Juan Li, Yuan Cao. Cell Cycle 2020
6
33


Epigenetic Regulation of m6A Modifications in Human Cancer.
Wei Zhao, Xiaoqian Qi, Lina Liu, Shiqing Ma, Jingwen Liu, Jie Wu. Mol Ther Nucleic Acids 2020
61
33

KIAA1429 regulates cell proliferation by targeting c-Jun messenger RNA directly in gastric cancer.
Ran Miao, Cong-Cong Dai, Lin Mei, Jun Xu, Shan-Wen Sun, Yun-Long Xing, Li-Sheng Wu, Ming-Hai Wang, Ji-Fu Wei. J Cell Physiol 2020
19
33

Application of targeted genome sequencing to brain metastasis from non-small cell lung carcinoma: Case report.
N Leclair, R Calafiore, Q Wu, L Wolansky, K R Bulsara. Neurochirurgie 2020
1
100


An Emerging Role of m6A in Memory: A Case for Translational Priming.
Amanda M Leonetti, Ming Yin Chu, Fiona O Ramnaraign, Samuel Holm, Brandon J Walters. Int J Mol Sci 2020
6
33

RNA m6 A methylation regulates sorafenib resistance in liver cancer through FOXO3-mediated autophagy.
Ziyou Lin, Yi Niu, Arabella Wan, Dongshi Chen, Heng Liang, Xijun Chen, Lei Sun, Siyue Zhan, Liutao Chen, Chao Cheng,[...]. EMBO J 2020
64
33

Oocyte competence is maintained by m6A methyltransferase KIAA1429-mediated RNA metabolism during mouse follicular development.
Yue Hu, Zhangyi Ouyang, Xuesong Sui, Meijie Qi, Mingrui Li, Yuanlin He, Yumeng Cao, Qiqi Cao, Qianneng Lu, Shuai Zhou,[...]. Cell Death Differ 2020
18
33


The m6A epitranscriptome opens a new charter in immune system logic.
Zhonghua Ma, Xiangyu Gao, You Shuai, Xiaofang Xing, Jiafu Ji. Epigenetics 2021
3
33

Epitranscriptomics in the Heart: a Focus on m6A.
Jacob Z Longenecker, Christopher J Gilbert, Volha A Golubeva, Colton R Martens, Federica Accornero. Curr Heart Fail Rep 2020
4
33


The m6A methyltransferase METTL3 contributes to Transforming Growth Factor-beta-induced epithelial-mesenchymal transition of lung cancer cells through the regulation of JUNB.
Sasithorn Wanna-Udom, Minoru Terashima, Hanbing Lyu, Akihiko Ishimura, Takahisa Takino, Matomo Sakari, Toshifumi Tsukahara, Takeshi Suzuki. Biochem Biophys Res Commun 2020
42
33

IGF2BP2 regulates DANCR by serving as an N6-methyladenosine reader.
Xiaoge Hu, Wan-Xin Peng, Huaixiang Zhou, Jiahong Jiang, Xinchun Zhou, Dongsheng Huang, Yin-Yuan Mo, Liu Yang. Cell Death Differ 2020
77
33

LncRNA MAGI2-AS3 Is Regulated by BRD4 and Promotes Gastric Cancer Progression via Maintaining ZEB1 Overexpression by Sponging miR-141/200a.
Dandan Li, Jingjie Wang, Meixin Zhang, Xinhui Hu, Jiajun She, Xuemei Qiu, Xudong Zhang, Li Xu, Ying Liu, Shanshan Qin. Mol Ther Nucleic Acids 2020
40
33

Sequential treatment with afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: an observational study.
Maximilian J Hochmair, Alessandro Morabito, Desiree Hao, Cheng-Ta Yang, Ross A Soo, James C-H Yang, Rasim Gucalp, Balazs Halmos, Lara Wang, Amanda Golembesky,[...]. Future Oncol 2018
68
33


Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence.
Tetsuya Mitsudomi, Takayuki Kosaka, Hideki Endoh, Yoshitsugu Horio, Toyoaki Hida, Shoichi Mori, Shunzo Hatooka, Masayuki Shinoda, Takashi Takahashi, Yasushi Yatabe. J Clin Oncol 2005
796
33

Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib.
F R Hirsch, M Varella-Garcia, F Cappuzzo, J McCoy, L Bemis, A C Xavier, R Dziadziuszko, P Gumerlock, K Chansky, H West,[...]. Ann Oncol 2007
230
33

The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies.
Matthew J Niederst, Haichuan Hu, Hillary E Mulvey, Elizabeth L Lockerman, Angel R Garcia, Zofia Piotrowska, Lecia V Sequist, Jeffrey A Engelman. Clin Cancer Res 2015
313
33

Lung cancer survival and stage at diagnosis in Australia, Canada, Denmark, Norway, Sweden and the UK: a population-based study, 2004-2007.
Sarah Walters, Camille Maringe, Michel P Coleman, Michael D Peake, John Butler, Nicholas Young, Stefan Bergström, Louise Hanna, Erik Jakobsen, Karl Kölbeck,[...]. Thorax 2013
292
33

Oncogenic drivers, targeted therapies, and acquired resistance in non-small-cell lung cancer.
Arjan Gower, Yisong Wang, Giuseppe Giaccone. J Mol Med (Berl) 2014
41
33

Blood-based tumor biomarkers in lung cancer for detection and treatment.
Hirva Mamdani, Shahid Ahmed, Samantha Armstrong, Tony Mok, Shadia I Jalal. Transl Lung Cancer Res 2017
29
33

Real-world management of patients with epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer in the USA.
Yulin Li, Anita Appius, Thirupathi Pattipaka, Andrea Feyereislova, Adrian Cassidy, Apar Kishor Ganti. PLoS One 2019
15
33

Biomarker Testing for Patients With Advanced Non-Small Cell Lung Cancer: Real-World Issues and Tough Choices.
Nathan A Pennell, Maria E Arcila, David R Gandara, Howard West. Am Soc Clin Oncol Educ Book 2019
75
33

Patterns of Biomarker Testing Rates and Appropriate Use of Targeted Therapy in the First-Line, Metastatic Non-Small Cell Lung Cancer Treatment Setting.
Casey Mason, Peter G Ellis, Kathy Lokay, Amanda Barry, Natalie Dickson, Ray Page, Blase Polite, Ravi Salgia, Michael Savin, Corey Shamah,[...]. J Clin Pathw 2018
12
33




Standard deviations and standard errors.
Douglas G Altman, J Martin Bland. BMJ 2005
223
33

EGFR T790M mutation: a double role in lung cancer cell survival?
Kenichi Suda, Ryoichi Onozato, Yasushi Yatabe, Tetsuya Mitsudomi. J Thorac Oncol 2009
112
33

EGFR testing in lung cancer is ready for prime time.
Fred R Hirsch, Paul A Bunn. Lancet Oncol 2009
137
33

Emergence of novel and dominant acquired EGFR solvent-front mutations at Gly796 (G796S/R) together with C797S/R and L792F/H mutations in one EGFR (L858R/T790M) NSCLC patient who progressed on osimertinib.
Sai-Hong Ignatius Ou, Jean Cui, Alexa B Schrock, Michael E Goldberg, Viola W Zhu, Lee Albacker, Philip J Stephens, Vincent A Miller, Siraj M Ali. Lung Cancer 2017
74
33


Osimertinib in T790M-positive and -negative patients with EGFR-mutated advanced non-small cell lung cancer (the TREM-study).
Inger Johanne Zwicky Eide, Åslaug Helland, Simon Ekman, Anders Mellemgaard, Karin Holmskov Hansen, Saulius Cicenas, Jussi Koivunen, Bjørn Henning Grønberg, Odd Terje Brustugun. Lung Cancer 2020
10
33

Second-line treatment of EGFR T790M-negative non-small cell lung cancer patients.
Bin-Chi Liao, Sebastian Griesing, James Chih-Hsin Yang. Ther Adv Med Oncol 2019
8
33

The APPLE Trial: Feasibility and Activity of AZD9291 (Osimertinib) Treatment on Positive PLasma T790M in EGFR-mutant NSCLC Patients. EORTC 1613.
Jordi Remon, Jessica Menis, Baktiar Hasan, Aleksandra Peric, Eleonora De Maio, Silvia Novello, Martin Reck, Thierry Berghmans, Bartosz Wasag, Benjamin Besse,[...]. Clin Lung Cancer 2017
63
33

Impact of TP53 Mutations on Outcome in EGFR-Mutated Patients Treated with First-Line Tyrosine Kinase Inhibitors.
Matteo Canale, Elisabetta Petracci, Angelo Delmonte, Elisa Chiadini, Claudio Dazzi, Maximilian Papi, Laura Capelli, Claudia Casanova, Nicoletta De Luigi, Marita Mariotti,[...]. Clin Cancer Res 2017
124
33

Real-world experience of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma.
Sheng-Kai Liang, Min-Shu Hsieh, Meng-Rui Lee, Li-Ta Keng, Jen-Chung Ko, Jin-Yuan Shih. Oncotarget 2017
39
33


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.